Randomised trials remain essential and are not overrated

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 2, 2011, Pages 129-131

  Armitage, J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HOMOCYSTINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STREPTOKINASE; TORCETRAPIB; VITAMIN B GROUP;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HUMAN; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; PUBLISHING; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; STROKE;

EID: 80052712320     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.216     Document Type: Article

References (25)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-60.
2. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. doi:10.1016/S0140-6736(02)09327-3
4. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78. doi:10.1016/S0140-6736(05)67394-1
5. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1998; 317:1170-1.
6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86. doi:10.1136/bmj.324.7329.71
7. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-38. doi:10.1016/0140-6736(90)90944-Z
8. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992; 339:71-85.
9. DeAngelis CD, Drazen JM, Frizelle FA et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004; 292:1363-4. doi:10.1001/jama.292.11.1363
10. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276:637-9. doi:10.1001/jama.276.8.637
11. Hopewell S, Dutton S, Yu LM et al. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010; 340:c723. doi:10.1136/bmj.c723
12. Stewart PM, Stears A, Tomlinson JW et al. Regulation-the real threat to clinical research. BMJ 2008; 337:a1732. doi:10.1136/bmj.a1732
13. Haynes R, Bowman L, Rahimi K et al. How the NHS research governance procedures could be modified to greatly strengthen clinical research. Clin Med 2010; 10:127-9.
14. Academy of Medical Sciences (AMS). A new pathway for the regulation and governance of health research. London: AMS; 2011. Available from: http://www.acmedsci.ac.uk/p47prid88.html
15. Brown ML, Gersh BJ, Holmes DR et al. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med 2008; 5:613-20. doi:10.1038/ncpcardio1307
16. Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet. 2000; 356:1627-31. doi:10.1016/S0140-6736(00)03155-X
17. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197. doi:10.1136/bmj.c2197
18. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-22. doi:10.1001/jama.288.16.2015
19. Clarke R, Halsey J, Lewington S et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170:1622-31. doi:10.1001/archinternmed.2010.348
20. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-22. doi:10.1056/NEJMoa0706628
21. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-12. doi:10.1056/ NEJM198908103210629
22. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-4. doi:10.1016/S0140-6736(02)11032-4
23. Edwards P, Arango M, Balica L et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365:1957-9.
24. Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Ann Med 2007; 39:18-27. doi:10.1080/07853890601073445
25. Macintyre S. Good intentions and received wisdom are not good enough: the need for controlled trials in public health. J Epidemiol Community Health 2010; epub ahead of print 8 Dec. doi:10.1136/ jech.2010.124198